Literature DB >> 27457482

Deep-sequencing revealing mutation dynamics in the miltefosine transporter gene in Leishmania infantum selected for miltefosine resistance.

Marie-Claude N Laffitte1, Philippe Leprohon1, Danielle Légaré1, Marc Ouellette2.   

Abstract

Miltefosine is the first oral drug used in chemotherapy against leishmaniasis. In vitro studies found that resistance to miltefosine in Leishmania is often associated with the acquisition of point mutations in the miltefosine transporter, leading to a decrease in drug uptake. In this study, the dynamics of mutations upon miltefosine selection was studied by deep-sequencing of the miltefosine transporter gene. Deep-sequencing data revealed that no mutation was detected in the miltefosine transporter at sub-inhibitory concentrations of miltefosine. We show that the prevalence of mutated alleles was increasing when the drug pressure heightened, that more mutations were observed in highly resistant mutants, and that most mutations remained when parasites were cultured for a few passages in the absence of miltefosine.

Entities:  

Keywords:  Deep-sequencing; Leishmania; Miltefosine transporter; Resistance

Mesh:

Substances:

Year:  2016        PMID: 27457482     DOI: 10.1007/s00436-016-5195-y

Source DB:  PubMed          Journal:  Parasitol Res        ISSN: 0932-0113            Impact factor:   2.289


  25 in total

1.  Short-course of oral miltefosine for treatment of visceral leishmaniasis.

Authors:  S Sundar; A Makharia; D K More; G Agrawal; A Voss; C Fischer; P Bachmann; H W Murray
Journal:  Clin Infect Dis       Date:  2000-10       Impact factor: 9.079

Review 2.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

3.  Experimental selection of paromomycin and miltefosine resistance in intracellular amastigotes of Leishmania donovani and L. infantum.

Authors:  S Hendrickx; G Boulet; A Mondelaers; J C Dujardin; S Rijal; L Lachaud; P Cos; P Delputte; L Maes
Journal:  Parasitol Res       Date:  2014-03-11       Impact factor: 2.289

4.  Miltefosine affects lipid metabolism in Leishmania donovani promastigotes.

Authors:  M Rakotomanga; S Blanc; K Gaudin; P Chaminade; P M Loiseau
Journal:  Antimicrob Agents Chemother       Date:  2007-01-22       Impact factor: 5.191

5.  Alterations in the homeostasis of phospholipids and cholesterol by antitumor alkylphospholipids.

Authors:  José M Jiménez-López; Pablo Ríos-Marco; Carmen Marco; Josefa L Segovia; María P Carrasco
Journal:  Lipids Health Dis       Date:  2010-03-25       Impact factor: 3.876

Review 6.  Leishmaniasis: current situation and new perspectives.

Authors:  P Desjeux
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2004-09       Impact factor: 2.268

7.  Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo.

Authors:  Karin Seifert; F Javier Pérez-Victoria; Marianne Stettler; María P Sánchez-Cañete; Santiago Castanys; Francisco Gamarro; Simon L Croft
Journal:  Int J Antimicrob Agents       Date:  2007-07-12       Impact factor: 5.283

8.  In vitro susceptibilities of Leishmania donovani promastigote and amastigote stages to antileishmanial reference drugs: practical relevance of stage-specific differences.

Authors:  Marieke Vermeersch; Raquel Inocêncio da Luz; Kim Toté; Jean-Pierre Timmermans; Paul Cos; Louis Maes
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

9.  Untargeted metabolomic analysis of miltefosine action in Leishmania infantum reveals changes to the internal lipid metabolism.

Authors:  Isabel M Vincent; Stefan Weidt; Luis Rivas; Karl Burgess; Terry K Smith; Marc Ouellette
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2013-12-05       Impact factor: 4.077

10.  In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.

Authors:  Adriano C Coelho; Cristiana T Trinconi; Carlos H N Costa; Silvia R B Uliana
Journal:  PLoS Negl Trop Dis       Date:  2014-07-17
View more
  9 in total

Review 1.  Plasticity of the Leishmania genome leading to gene copy number variations and drug resistance.

Authors:  Marie-Claude N Laffitte; Philippe Leprohon; Barbara Papadopoulou; Marc Ouellette
Journal:  F1000Res       Date:  2016-09-20

2.  In vitro drug susceptibility of two strains of the wildlife trypanosome, Trypanosoma copemani: A comparison with Trypanosoma cruzi.

Authors:  Adriana Botero; Sarah Keatley; Christopher Peacock; R C Andrew Thompson
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-12-23       Impact factor: 4.077

Review 3.  Leishmaniasis in humans: drug or vaccine therapy?

Authors:  Masoud Ghorbani; Ramin Farhoudi
Journal:  Drug Des Devel Ther       Date:  2017-12-22       Impact factor: 4.162

4.  Genomic and transcriptomic alterations in Leishmania donovani lines experimentally resistant to antileishmanial drugs.

Authors:  Alberto Rastrojo; Raquel García-Hernández; Paola Vargas; Esther Camacho; Laura Corvo; Hideo Imamura; Jean-Claude Dujardin; Santiago Castanys; Begoña Aguado; Francisco Gamarro; Jose M Requena
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2018-04-13       Impact factor: 4.077

5.  Single-Strand Annealing Plays a Major Role in Double-Strand DNA Break Repair following CRISPR-Cas9 Cleavage in Leishmania.

Authors:  Wen-Wei Zhang; Greg Matlashewski
Journal:  mSphere       Date:  2019-08-21       Impact factor: 4.389

6.  Investigation of the pathways related to intrinsic miltefosine tolerance in Leishmania (Viannia) braziliensis clinical isolates reveals differences in drug uptake.

Authors:  Caroline R Espada; Rubens M Magalhães; Mario C Cruz; Paulo R Machado; Albert Schriefer; Edgar M Carvalho; Valentín Hornillos; João M Alves; Angela K Cruz; Adriano C Coelho; Silvia R B Uliana
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2019-02-25       Impact factor: 4.077

7.  Antileishmanial Aminopyrazoles: Studies into Mechanisms and Stability of Experimental Drug Resistance.

Authors:  M Van den Kerkhof; D Mabille; S Hendrickx; P Leprohon; C E Mowbray; S Braillard; M Ouellette; L Maes; G Caljon
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

Review 8.  Impact of Genetic Diversity and Genome Plasticity of Leishmania spp. in Treatment and the Search for Novel Chemotherapeutic Targets.

Authors:  Ana Maria Murta Santi; Silvane Maria Fonseca Murta
Journal:  Front Cell Infect Microbiol       Date:  2022-01-24       Impact factor: 5.293

9.  Downregulation of FeSOD-A expression in Leishmania infantum alters trivalent antimony and miltefosine susceptibility.

Authors:  Ana Maria Murta Santi; Paula Alves Silva; Isabella Fernandes Martins Santos; Silvane Maria Fonseca Murta
Journal:  Parasit Vectors       Date:  2021-07-15       Impact factor: 3.876

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.